title: [Pancreatic secretory trypsin inhibitor in urothelial cancer].
abstract: Pancreatic secretory trypsin inhibitor (PSTI) levels are known to increase in some kinds of cancer. We determined the PSTI levels in patients with urothelial cancer to evaluate its usefulness as a tumor marker. The subjects were 101 patients who had bladder cancer (n = 81) or renal pelvis and ureter cancer (n = 20). Twenty-six healthy volunteers were used as controls. PSTI was measured by an RI kit using the double antibody method, and levels above 20 ng/ml were taken as positive. Serum tissue polypeptide antigen (TPA) levels were also measured in 32 cases. None of the controls, 65% of the patients with renal pelvis and ureter cancer, and 30.9% of bladder cancer had positive levels of PSTI. The positive rate for each stage was 22.3% for Tis, Taand T1, 38.5% for T2, 73.3% for T3 and 100% for T4. The rate tended to increase with the progress of tumor infiltration. All subjects with positive readings above 30 ng/ml had progressive cancer. The usefulness of PSTI as a tumor marker was similar to that of TPA. PSTI is not a specific marker of urothelial cancer, but it showed an association with the progression of cancer. Therefore, it is considered to be a useful marker to determine postoperative metastasis, recurrence, and disease progression.
authors.affiliation: Department of Urology, Atsugi Prefectural Hospital.
authors.forename: K
authors.initials: K
authors.lastname: Tashiro
authors.forename: S
authors.initials: S
authors.lastname: Torii
authors.forename: S
authors.initials: S
authors.lastname: Iwamuro
authors.forename: Y
authors.initials: Y
authors.lastname: Ohishi
authors.forename: N
authors.initials: N
authors.lastname: Hasegawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kawashima
authors.forename: A
authors.initials: A
authors.lastname: Mochizuki
authors.forename: H
authors.initials: H
authors.lastname: Yoshigoe
authors.forename: T
authors.initials: T
authors.lastname: Wada
authors.forename: T
authors.initials: T
authors.lastname: Machida
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000473:pathology; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000473:pathology; D007682:Kidney Pelvis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011863:Radioimmunoassay; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood*; D014361:Trypsin Inhibitors / Q000097:blood*; D014516:Ureteral Neoplasms / Q000175:diagnosis / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D014361:Trypsin Inhibitors; D014359:Trypsin Inhibitor, Kazal Pancreatic